2025
SJR Q1
JCR Q1 · 4,3
5 matched articles
SCIE
Journal detail
Expert Review of Neurotherapeutics
- Publisher
- Taylor and Francis Ltd.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
1473717517448360
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,106
- Quartile Q1
- H-Index 110
- Cites/doc 4,13
- Docs (3y) 299
- Cites (3y) 1.192
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 4,3
- 5Y JIF 4,3
- JCI 0,68
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Neurology (clinical) Q1
- Neuroscience (miscellaneous) Q2
- Pharmacology (medical) Q1
Areas
- Medicine
- Neuroscience
WoS categories
- Clinical Neurology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,106 | 4,3 | 4,3 | 0,68 | Q2 | 110 |
| 2024 | Q1 | Q2 | 1,162 | 3,4 | 3,9 | 0,68 | Q2 | 103 |
| 2023 | Q1 | Q2 | 0,957 | 3,4 | 4,6 | 0,64 | Q3 | 103 |
| 2022 | Q1 | Q2 | 0,995 | 4,3 | 4,4 | 0,62 | Q3 | 103 |
| 2021 | Q1 | Q2 | 1,02 | 4,3 | 4,5 | 0,6 | Q3 | 103 |
| 2020 | Q1 | Q2 | 1,187 | 4,6 | 4,5 | 0,65 | Q3 | 103 |
| 2019 | Q1 | Q2 | 1,101 | 3,7 | 3,5 | 0,66 | Q3 | 103 |
| 2018 | — | Q2 | — | 3,5 | 3,1 | 0,67 | Q3 | — |
| 2017 | Q2 | Q1 | 1,006 | 3,7 | 3,2 | 0,58 | Q3 | 103 |
| 2016 | Q1 | Q2 | 1,102 | 3,1 | 3,1 | — | — | 103 |
| 2015 | Q2 | Q2 | 1,037 | 2,6 | 2,8 | — | — | 103 |
| 2014 | Q1 | Q2 | 1,069 | 2,8 | 3,1 | — | — | 103 |
| 2013 | Q1 | Q2 | 1,077 | 2,8 | — | — | — | 103 |
| 2012 | Q1 | Q2 | 1,157 | 3 | — | — | — | 103 |
| 2011 | Q1 | — | 1,162 | — | — | — | — | 103 |
| 2010 | Q1 | — | 0,956 | — | — | — | — | 103 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q1 | Q3 | 57/296 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 95/356 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 78/286 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 113/352 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 75/280 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 105/354 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 59/212 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 87/278 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 83/212 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 103/279 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 57/208 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 78/276 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 53/204 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 70/271 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 60/199 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 75/267 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q1 | Q3 | 49/197 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q3 | 54/261 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 64/194 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 76/257 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 83/193 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 103/255 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 71/192 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 96/255 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 66/194 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/256 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 61/193 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 77/261 |